1. 1. World Health Organization (WHO) (2006): WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly. Epidemiol. Rec., 47, 445–452.
2. 2. Siber, G.R., Anderson, R., Habafy, M., et al. (1995): Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine, 16, 525–531.
3. 3. Shams, H. and Heron, I. (1999): Mutual interactions between DTaP-IPV and Haemophilus influenzae type b (Hib)-conjugated vaccines in laboratory animal models. Biologicals, 27, 227–240.
4. 4. Redead, K., Sesardic, D., Yost, S.E., et al. (1994): Interaction of Haemophilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests. Vaccine, 12, 1460–1466.
5. 5. World Health Organization (WHO) (2000): Introduction of Haemophilus influenzae Type b Vaccine into Immunization Programmes. Management Guidelines, including Information for Health Workers and Parents. WHO/V&B/00.05. WHO (Department of Vaccines and Biologicals), Geneva.